The PACMAN-AMI trial (Effects of the PCSK9 Antibody Alirocumab on CoronaryAtherosclerosis in Patients with Acute Myocardial Infarction) showed a similareffect of alirocumab on plaque composition. Here, PCSK9 is linked to myocardial infarction.